Revenue segments as reported by the company.

Pharmaceutical

Animal Health

Other Revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Restructuring costs

Other (income) expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Merck

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Merck reports robust Q4 earnings, eyes growth through innovation

Merck's Q4 2022 performance reflects strong revenue growth and strategic advancements across key therapeutic areas, positioning the company for future success.
While facing challenges such as patent estate concerns and competitive pressures, Merck's focus on innovation and partnerships presents opportunities for sustained growth.
Analyst inquiries and executive responses during the earnings call highlight the company's commitment to transparency, patient outcomes, and shareholder value.

Merck reports robust Q1 earnings, eyes growth in oncology and vaccines

Merck's Q1 performance reflects strong revenue growth driven by oncology and vaccines, with a raised full-year guidance and focus on pipeline advancements.
The company's strategic strengths lie in its focus on compelling science, value alignment in business decisions, and commitment to innovation.
Challenges include potential impacts of EU legislation, post-KEYTRUDA LOE growth strategies, and navigating regulatory complexities for new treatments.
Opportunities in expansion in China, revenue diversification, innovative combination therapies, and protective treatment strategies position Merck for future growth.

Merck reports robust Q2 earnings, focuses on growth opportunities

Merck's Q2 performance showcased strong earnings driven by Oncology and Vaccines growth
Despite challenges like regulatory concerns and price pressures, the company remains focused on innovation
Opportunities lie in expanding KEYTRUDA's reach in cancer indications and advancing in immunology
Overall, Merck's strategic acquisitions and commitment to growth position it well for the future

Merck reports robust Q3 earnings, eyes growth in precision medicine

Merck's Q3 2023 Earnings Call highlighted strong revenue growth, pipeline advancements, and increased full-year revenue guidance. The company's strategic focus on key therapeutic areas and precision medicine approaches positions it for continued success and innovation.

Merck reports robust Q4 earnings, eyes growth through strategic investments

Merck's strong Q4 performance was driven by KEYTRUDA and Vaccines, with positive revenue guidance for 2024. The company remains focused on R&D advancements, strategic investments, and shareholder value. Challenges include managing expenses and maximizing market opportunities.

Merck reports robust Q1 earnings, eyes growth in innovative treatments

Merck's Q1 performance reflects strong revenue growth, operational efficiency, and a positive outlook for future earnings.
The company's focus on innovation, strategic investments, and commitment to patient access position it well for long-term success.
Challenges in pipeline differentiation and market competition require continued strategic planning and differentiation strategies.
Opportunities in new treatment areas, market expansion, and upcoming events offer avenues for sustained growth and market leadership.

Merck reports robust Q2 earnings, eyes future drug launches

Merck's Q2 earnings call highlighted strong financial performance, innovative product launches, and confidence in future growth. The company addressed analyst inquiries, emphasizing long-term pipeline growth and short-term financial guidance while expressing gratitude for investor support.

Merck reports solid Q3 earnings, eyes growth through diversification

Merck's Q3 2024 performance reflects revenue growth driven by key products and clinical advancements, despite regional sales variations and inventory challenges.
The company's strengths in diversification, clinical progress, and strategic investments position it well for future growth and competitive edge in the market.
While facing challenges in specific product sales and clinical trials, Merck has opportunities to capitalize on its strengths, expand offerings, and drive sustained growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck & Co. Inc. MRK, -1.66% and Eisai Co. Ltd. ESALF, +3.00% said Friday that a late-stage trial of Merck's blockbuster cancer treatment Keytruda in combination with Eisai's drug Lenvima failed to meet its primary goals for treatment of certain types of endometrial cancer.

Merck and Eisai combination endometrial cancer treatment fails to meet goals in clinical trial

Merck said on Friday its experimental combination therapy being developed with partner Eisai to treat a type of cancer in the lining of the uterus failed to meet the main goals in a late-stage study.

Merck-Eisai's cancer therapy combo fails in late-stage study

RAHWAY, N.J., & NUTLEY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck and Eisai Provide Update on LEAP-001 Trial Evaluating KEYTRUDA + LENVIMA as First-Line Treatment for Advanced or Recurrent Endometrial Carcinoma.

Merck and Eisai Provide Update on Phase 3 LEAP-001 Trial Evaluating (pembrolizumab) Plus LENVIMA® (lenvatinib) as First-Line Treatment for Patients with Advanced or Recurrent Endometrial Carcinoma

Air Lease

Avient Corp

ChoiceOne Financial Services Inc

Capital Southwest

Devon Energy

Fidelity National Financial

Leidos Hld

Motorola Solutions

NexPoint Residential Trust

Prosperity Bancshares

Regency Centers

Sonic Automotive

Schwab US Dividend Equity ETF

Hanover Insurance Group

December is the last opportunity for companies to announce yearly dividend increases. 15 companies expected to raise their dividends in the upcoming week, with a focus on up-and-comers in the dividend growth space. The companies feature an average increase of 8.6% and a median increase of 4.9%.

15 Upcoming Dividend Increases

Merck & Co Inc (NYSE:MRK) announced on Thursday that its investigational lung cancer therapeutic combination of pembrolizumab (Keytruda) and vibostolimab failed to meet the goal of a mid-stage study. Vibostolimab is an investigational anti-TIGIT antibody that Merck said restores antitumor activity by blocking the TIGIT receptor from binding to its ligands (CD112 and CD155), activating T lymphocytes that assist in destroying tumor cells.

Merck cancels Phase 3 lung cancer study on disappointing interim data as separate mid-stage trial fails

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that it will stop the Phase 3 KEYLYNK-008 trial evaluating KEYTRUDA, Merck's anti-PD-1 therapy, in combination with maintenance LYNPARZA, a PARP inhibitor, for the treatment of patients with metastatic squamous non-small cell lung cancer (NSCLC). Merck is discontinuing the study based on the recommendation of an independent Data Monitoring Committee (DMC), which reviewed data.

Merck Announces KEYLYNK-008 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LYNPARZA® (olaparib) for Patients With Metastatic Squamous Non-Small Cell Lung Cancer to Stop for Futility

Merck said on Thursday its experimental therapy in combination with Keytruda to treat a type of lung cancer in previously treated patients did not reach statistical significance in a mid-stage study.

Merck's lung cancer drug combo fails to meet trial goal

RAHWAY, N.J.--(BUSINESS WIRE)--Merck Announces Findings from Ph 2 KeyVibe-002 Trial Evaluating Investigational Coformulation Vibostolimab/Pembrolizumab in Previously Treated mNSCLC.

Merck Announces Findings from Phase 2 KeyVibe-002 Trial Evaluating an Investigational Coformulation of Vibostolimab and Pembrolizumab in Previously Treated Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC)

German stocks rose in early trade on Wednesday, extending gains after finishing at a record amid signs that interest rates will fall in both Europe and the U.S.

German stocks rise after ending at a record high

DARMSTADT, Germany--(BUSINESS WIRE)--Merck, a leading science and technology company, today announced that its two Phase III EVOLUTION clinical trials (evolutionRMS 1 and evolutionRMS 2) investigating the efficacy and safety of evobrutinib did not meet their primary endpoints of reducing annualized relapse rates (ARR) in people with relapsing multiple sclerosis (RMS) compared to oral teriflunomide (0.11 vs. 0.11 in evolutionRMS 1 and 0.15 for evobrutinib and 0.14 for teriflunomide in evolutionR.

Merck Provides Update on Phase III Results for Evobrutinib in Relapsing Multiple Sclerosis

Fastenal

McCormick

NIKE

PulteGroup

Dividend growth stocks consistently increase their dividend year after year with a 5-year growth rate of 10% or more. Companies must generate strong free cash flow to sustain dividend growth. All 5 of these stocks have recently increased their dividend, with the largest increase being as high as 25%.

5 Stocks That Recently Increased Their Dividend

SHANGHAI , Dec. 4, 2023 /PRNewswire/ -- On 4 Dec. 2023, Abbisko Therapeutics announced that it has entered into a licensing agreement with Merck, a leading science and technology company headquartered in Darmstadt, Germany. Under the terms of the agreement, Merck will be granted an exclusive license to commercialize products comprising or containing pimicotinib (ABSK021) for all indications in Chinese mainland, Hong Kong, Macau and Taiwan (the "Licensed Territory"), and Abbisko Therapeutics will retain the exclusive rights to develop pimicotinib within the Licensed Territory.

Abbisko Therapeutics Announced the Entry into a Licensing Agreement for Pimicotinib (ABSK021) with Merck

DARMSTADT, Germany--(BUSINESS WIRE)--Merck, a leading science and technology company, today announced a license agreement with Abbisko Therapeutics Co. Ltd., Shanghai, China, for pimicotinib (ABSK021), which is currently being evaluated in a Phase III study for the treatment of tenosynovial giant cell tumor (TGCT). TGCT is a benign tumor of the joints that can cause swelling, pain, stiffness, and limited mobility of the affected joints. Treatment options for this disease, which can seriously af.

Merck Strengthens Oncology Portfolio Through Commercialization Agreement With Abbisko for Phase III Asset, Pimicotinib

Amgen

Cisco Systems

Chevron

Dow Inc

Goldman Sachs

Johnson & Johnson

Coca-Cola

Verizon

Walgreens

Walmart

"The Dow [adds a stock] if the company has an excellent reputation, demonstrates sustained growth, and is of interest to a large number of investors. Sector representation is also a consideration.” – Dow Jones & Co. The highest-yield 10 stocks are December's Dogs of the Dow: KO, AMGN, CSCO, GS, IBM, CVX, DOW, MMM, VZ, and WBA. They only averaged a 4.92% annual yield, as December prices rose. Thirty Dow stocks represent nine of eleven sectors. Dow Jones tracks utilities as a separate index and omits real estate. Broker top-ten target-estimated December net gains ranged between 11.08%-44.04%, topped by WBA 11/30/23.

December Dogs Of The Dow: 3 Buyable, 5 Watchable

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--FDA Grants Priority Review to Merck's Application for KEYTRUDA Plus Padcev for the First-Line Treatment of Patients With Advanced Urothelial Cancer.

FDA Grants Priority Review to Merck's Application for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) for the First-Line Treatment of Patients With Locally Advanced or Metastatic Urothelial Cancer

Apartment Income REIT Corp

Alexandria Real Estate Equities

AstraZeneca

COPT Defense Properties

Gilead Sciences

Gaming and Leisure Properties

Healthcare Realty Trust Inc

Host Hotels & Resorts

Johnson Controls

LTC Properties

Banco Santander

Sabra Health Care

Telia Co AB

V.F.

Vici Properties

Telefonica Brasil

September-October, 2023, Barron's, Bloomberg, and Fortune analysts and reporters combined to list five sets of stocks sorted as “Recovery Bets.” Those five articles revealed 53 equities, with 42 paying-dividends. These recovery lists focus on financial services, healthcare, and real estate sectors by Barron's along with selected “change the world” stocks from Fortune and ten to watch from Bloomberg.

17 Ideal Pre-Crash Recovery December Divi-Dogs

Merck & Co., Inc. (NYSE:MRK ) 6th Annual Evercore ISI HealthCONx Conference Transcript November 30, 2023 1:20 PM ET Executives Dr. Eliav Barr - Senior Vice President, Head, Global Clinical Development and CMO Peter Dannenbaum - Vice President, Investor Relations Analysts Umer Raffat - Evercore Umer Raffat Thank you. Listen, thank you guys for being here.

Merck & Co., Inc. (MRK) Management Presents at 6th Annual Evercore ISI HealthCONx Conference (Transcript)

Positive data from Merck's (MRK) phase III study on V116, an investigational, 21-valent pneumococcal conjugate vaccine, supports the immunogenicity of V116 compared to standard of care.

Merck's (MRK) Pneumococcal Jab Shows Upbeat Responses in Study

Merck & Co. Inc. MRK said Tuesday its board has raised its quarterly dividend to 77 cents. The dividend was previously 73 cents.

Merck raises quarterly dividend to 77 cents vs. 73 cents

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Announces First-Quarter 2024 Dividend.

Merck Announces First-Quarter 2024 Dividend

Digital Realty Trust

Estee Lauder

Paramount Global

Pfizer

Stanley Black & Decker

Tyson Foods

It's only November — but if you're like most investors — 2024 is what matters now. And some S&P 500 companies already look primed to put up big numbers.

7 Companies Will Propel Profit More Than 100% Next Year: Analysts

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck's V116 an Investigational 21-valent PCV Demonstrated Superior Immunogenicity for 10 of 11 Unique Serotypes Compared to PCV20 in Adults 50+.

Merck's V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed to Protect Adults, Demonstrated Superior Immunogenicity for 10 of 11 Unique Serotypes Compared to PCV20 in Adults 50 Years of Age and Older

Duke Energy

At first blush, focusing on low-volatility stocks may appear an overly pessimistic strategy. After all, the benchmark S&P 500 gained almost 8% in the trailing month.

Stability Seekers: 7 Low-Volatility Stocks for Uncertain Times

News for Merck Stock (MRK)